Gene silencing approaches for the management of dyslipidaemia

QR Code

Gene silencing approaches for the management of dyslipidaemia

The key role of dyslipidaemias in determining cardiovascular risk has been well established, and statins often provide effective therapeutic management. However, many patients do not achieve recommended lipid levels despite maximal therapy, and some cannot tolerate high-dose statin therapy. Recently...

Full description

Bibliographic Details
Main Authors:	Norata, Giuseppe, Tibolla, G., Catapano, A.
Format:	Journal Article
Published:	2013
Online Access:	http://hdl.handle.net/20.500.11937/56265

Similar Items

New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs
by: Norata, Giuseppe, et al.
Published: (2013)

Targeting PCSK9 for hypercholesterolemia
by: Norata, Giuseppe, et al.
Published: (2014)

Statins and skeletal muscles toxicity: From clinical trials to everyday practice
by: Norata, Giuseppe, et al.
Published: (2014)

PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
by: Norata, Giuseppe, et al.
Published: (2014)

Re: Managing dyslipidaemia for the primary prevention of cardiovascular disease
by: Hippisley-Cox, Julia
Published: (2018)

Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?
by: Catapano, A., et al.
Published: (2017)

HDL: To treat or not to treat?
by: Pirillo, A., et al.
Published: (2014)

Dyslipidaemia In Patients With Type 2 Diabetes Mellitus.
by: Eid, M, et al.
Published: (2003)

Therapy and clinical trials: Aggressive statin therapy versus combined and emerging approaches
by: Catapano, A., et al.
Published: (2011)

Leonurine: A new comer in the natural compounds affecting atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2012)

Statins and periodontal inflammation: A pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?
by: Norata, Giuseppe, et al.
Published: (2014)

HDL and adaptive immunity: A tale of lipid rafts
by: Norata, Giuseppe, et al.
Published: (2012)

Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
by: Tibolla, G., et al.
Published: (2011)

Current insights on dyslipidaemia management for prevention of atherosclerotic cardiovascular disease: a malaysian perspective
by: Wan Ahmad, Wan Azman, et al.
Published: (2023)

Silence and silencing: the case of trafficked women
by: Haezreena Begum Abdul Hamid,
Published: (2019)

Cartographies of silence: mapping concepts of silence and their contexts
by: Brown, Melissa Shani
Published: (2013)

The sound of silence: Activating silent biosynthetic gene clusters in marine microorganisms
by: Reen, F., et al.
Published: (2015)

The CD1d-natural killer T cell axis in atherosclerosis
by: Bondarenko, S., et al.
Published: (2014)

Transgene Silencing Following Lentiviral Gene Delivery into Hematopoietic Stem Cells
by: Ngai, Siew Chang
Published: (2011)

Performance of engineering plant virus resistance: miRNA gene silencing
by: Mohamed, Elizah, et al.
Published: (2022)

Redressing the Silence
by: Carpenter, Paul
Published: (2013)

Silencing the Ulama
by: Hussain, Mohd. Yusof
Published: (2012)

The Power of Silence
by: Chrulew, Matthew
Published: (2014)

High-density lipoprotein subfractions - What the clinicians need to know
by: Pirillo, A., et al.
Published: (2013)

LOX-1, OxLDL, and atherosclerosis
by: Pirillo, A., et al.
Published: (2013)

Treating high density lipoprotein cholesterol (HDL-C): Quantity versus quality
by: Pirillo, A., et al.
Published: (2013)

Postprandial lipemia as a cardiometabolic risk factor
by: Pirillo, A., et al.
Published: (2014)

Vascular inflammation and low-density lipoproteins: Is cholesterol the link? A lesson from the clinical trials
by: Catapano, A., et al.
Published: (2017)

Novel concepts in HDL pharmacology
by: Remaley, A., et al.
Published: (2014)

Niemann-pick C1-like 1 (NPC1L1) inhibition and cardiovascular diseases
by: Pirillo, A., et al.
Published: (2016)

HDLs, immunity, and atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2011)

HDL in infectious diseases and sepsis
by: Pirillo, A., et al.
Published: (2015)

Strategies for the use of nonstatin therapies
by: Pirillo, A., et al.
Published: (2017)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives
by: Catapano, A., et al.
Published: (2017)

Relationship between dyslipidaemia and glycaemic status in patients with type 2 diabetes mellitus
by: Chellappah Thambiah, Subashini, et al.
Published: (2016)

High density lipoproteins and atherosclerosis: Emerging aspects
by: Sala, F., et al.
Published: (2012)

Tumour suppressive effects of WEE1 gene silencing in breast cancer cells.
by: Ghiasi, Naghmeh, et al.
Published: (2013)

The association of vitamin D status with dyslipidaemia and biomarkers of endothelial cell activation in older Australians
by: Alyami, Ali Mahdi, et al.
Published: (2016)

Awareness, knowledge and practice of dyslipidaemia management among postgraduate primary care trainees in Malaysia: a cross-sectional study
by: Said, Abdul Hadi, et al.
Published: (2017)

RNAi-mediated gene silencing of lanosterol 14α- demethylase (ERG11)-encoding gene in ganoderma boninense
by: Lim, Fook Hwa
Published: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lkpribei6ta7ejf21p3v35oo4v